Phase III OA data for CrystalGenomics' polmacoxib

CrystalGenomics Inc. (KOSDAQ:083790) said once-daily oral polmacoxib (formerly CG100649) was non-inferior to once-daily celecoxib and superior to placebo on the primary endpoint in a Phase III trial to treat osteoarthritis (OA). The primary endpoint was the change from baseline to week six in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score in the index joints. The double-blind, South Korean trial enrolled 362 patients with OA of the knee or hip.

This half, CrystalGenomics plans to submit an NDA to South Korea's Ministry of Food and Drug Safety (MFDS) for the dual-acting cyclooxygenase-2 (COX-2) and carbonic anhydrase inhibitor to treat OA. CrystalGenomics was up W1.35 (12%) to W13.05 on Thursday. ...